Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline with short-course radiotherapy for rectal cancer
ACTRN12620000815965Phase 2Not yet recruiting
- Sponsor
- Dr Natalie Briggs
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxycycline in rectal cancer and rectal adenocarcinoma, sponsored by Dr Natalie Briggs. Primary endpoint: Difference in mean CD133 H-score in resected tumours. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
doxycycline
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on ACTRN12620000815965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000815965.